This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Motzer, R. J. Articles by Reuter, V. Search for Related Content PubMed PubMed Citation Articles by Motzer, R. J. Articles by Reuter, V.

Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non–Clear-Cell Histology

From the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine; and Departments of Epidemiology and Biostatistics, Urology, and Pathology, Memorial Sloan-Kettering Cancer Center; and Department of Medicine, Cornell University Medical College, New York, NY.

Address reprint requests to Robert J. Motzer, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; email: motzerr{at}mskcc.org

PURPOSE: To define outcome data for patients with metastatic renal cell carcinoma (RCC) with histology other than clear-cell type, including collecting duct (or medullary carcinoma), papillary, chromophobe, and unclassified histologies.

PATIENTS AND METHODS: Sixty-four patients with metastatic non–clear-cell RCC histology were the subjects of this retrospective review. Included in the analysis were 22 (8%) of 286 patients from a clinical trials database, 19 of 1,166 patients from a surgery database, and 23 of 357 patients from a pathology database.

RESULTS: The prevalent histology was collecting duct, present in 26 (41%) patients. The number of patients with chromophobe and papillary histologies was 12 (19%) and 18 (28%), respectively. Eight (12%) of the patients had tumors that could not be classified for specific tumor histology. Among the 43 patients treated with 86 systemic therapies, including 37 cytokine therapies, two patients (5%) were observed to have a partial response. The median overall survival time was 9.4 months (95% confidence interval, 8 to 14 months). The survival was longer for patients with chromophobe tumors compared with collecting duct or papillary histology, and this group included four patients with survival of greater than 3 years.

CONCLUSION: RCC consists of a heterogeneous group of tumors including clear-cell, papillary, chromophobe, collecting duct, and unclassified cell types. Non–clear-cell histologies constitute less than 10% of patients in general populations of patients with advanced RCC treated on clinical trials. Metastatic non–clear-cell RCC is characterized by a resistance to systemic therapy and poor survival, with the survival for patients with chromophobe tumors longer than that for patients with metastatic collecting duct or papillary RCC. Treatment with novel agents on clinical trials is warranted.

This article has been cited by other articles:

				D. Strumberg Efficacy of Sunitinib and Sorafenib in Non-Clear Cell Renal Cell Carcinoma: Results From Expanded Access Studies J. Clin. Oncol., July 10, 2008; 26(20): 3469 - 3471. [Full Text] [PDF]

				T. K. Choueiri, A. Plantade, P. Elson, S. Negrier, A. Ravaud, S. Oudard, M. Zhou, B. I. Rini, R. M. Bukowski, and B. Escudier Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma J. Clin. Oncol., January 1, 2008; 26(1): 127 - 131. [Abstract] [Full Text] [PDF]

				W. K. Rathmell, W. M. Stadler, and B. I. Rini Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer ASCO Educational Book, January 1, 2008; 2008(1): 192 - 198. [Abstract] [Full Text] [PDF]

				J. Zhang, R. A. Lefkowitz, N. M. Ishill, L. Wang, C. S. Moskowitz, P. Russo, H. Eisenberg, and H. Hricak Solid Renal Cortical Tumors: Differentiation with CT Radiology, August 1, 2007; 244(2): 494 - 504. [Abstract] [Full Text] [PDF]

				T. Choueiri, B. Rini, J. Garcia, R. Baz, R. Abou-Jawde, S. Thakkar, P Elson, T. Mekhail, M Zhou, and R. Bukowski Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma Ann. Onc., February 1, 2007; 18(2): 249 - 255. [Abstract] [Full Text] [PDF]

				J. Jones and T. A. Libermann Genomics of Renal Cell Cancer: The Biology Behind and the Therapy Ahead Clin. Cancer Res., January 15, 2007; 13(2): 685s - 692s. [Abstract] [Full Text] [PDF]

				D. F. McDermott Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 716s - 720s. [Abstract] [Full Text] [PDF]

				M. Parton, M. Gore, and T. Eisen Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5584 - 5592. [Abstract] [Full Text] [PDF]

				S. E. Eggener, O. Yossepowitch, J. A. Pettus, M. E. Snyder, R. J. Motzer, and P. Russo Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence J. Clin. Oncol., July 1, 2006; 24(19): 3101 - 3106. [Abstract] [Full Text] [PDF]

				E. A. Ronnen, G. V. Kondagunta, and R. J. Motzer Medullary Renal Cell Carcinoma and Response to Therapy With Bortezomib J. Clin. Oncol., March 20, 2006; 24(9): e14 - e14. [Full Text] [PDF]

				H. T. Cohen and F. J. McGovern Renal-Cell Carcinoma N. Engl. J. Med., December 8, 2005; 353(23): 2477 - 2490. [Full Text] [PDF]

				X. J. Yang, M.-H. Tan, H. L. Kim, J. A. Ditlev, M. W. Betten, C. E. Png, E. J. Kort, K. Futami, K. A. Furge, M. Takahashi, et al. A Molecular Classification of Papillary Renal Cell Carcinoma Cancer Res., July 1, 2005; 65(13): 5628 - 5637. [Abstract] [Full Text] [PDF]

				A. N. Schuetz, Q. Yin-Goen, M. B. Amin, C. S. Moreno, C. Cohen, C. D. Hornsby, W. L. Yang, J. A. Petros, M. M. Issa, J. G. Pattaras, et al. Molecular Classification of Renal Tumors by Gene Expression Profiling J. Mol. Diagn., May 1, 2005; 7(2): 206 - 218. [Abstract] [Full Text] [PDF]

				J.-J. Patard, E. Leray, N. Rioux-Leclercq, L. Cindolo, V. Ficarra, A. Zisman, A. De La Taille, J. Tostain, W. Artibani, C. C. Abbou, et al. Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience J. Clin. Oncol., April 20, 2005; 23(12): 2763 - 2771. [Abstract] [Full Text] [PDF]

				R. J. Motzer, J. Bacik, and M. Mazumdar Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma: Memorial Sloan-Kettering Cancer Center Experience Clin. Cancer Res., September 15, 2004; 10(18): 6302S - 6303S. [Abstract] [Full Text] [PDF]

				J. S. Lam, A. S. Belldegrun, and R. A. Figlin Tissue Array-Based Predictions of Pathobiology, Prognosis, and Response to Treatment for Renal Cell Carcinoma Therapy Clin. Cancer Res., September 15, 2004; 10(18): 6304S - 6309S. [Abstract] [Full Text] [PDF]

				W. M. Stadler Therapeutic Options for Variant Renal Cancer: A True Orphan Disease Clin. Cancer Res., September 15, 2004; 10(18): 6393S - 6396S. [Abstract] [Full Text] [PDF]

				R. J. Motzer, J. Bacik, L. H. Schwartz, V. Reuter, P. Russo, S. Marion, and M. Mazumdar Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., February 1, 2004; 22(3): 454 - 463. [Abstract] [Full Text] [PDF]

				S. D. W. Beck, M. I. Patel, M. E. Snyder, M. W. Kattan, R. J. Motzer, V. E. Reuter, and P. Russo Effect of Papillary and Chromophobe Cell Type on Disease-Free Survival After Nephrectomy for Renal Cell Carcinoma Ann. Surg. Oncol., January 1, 2004; 11(1): 71 - 77. [Abstract] [Full Text] [PDF]